COMPANY NEWS

Two Posters Featuring MyoStrain Presented at ESC Heart Failure Congress 2019

Athens, Greece, May 29, 2019 – Myocardial Solutions’ MyoStrain was featured in two different posters presented at the European Society of Cardiology's annual Heart Failure Congress 2019. The event was held in Athens, Greece on May 25-28, 2019. The lead author of the abstracts was Dr. Henning Steen, Head of Cardiac Imaging at Marien Hospital (Hamburg, Germany).  

Links to the posters are provided below:

Title: Prevention of heart failure with cardioprotective therapy after early detection of cardiotoxicity during chemotherapy in cancer patients using CMR Fast-SENC intramyocardial LV and RV strain

Citation: Steen H, et al. Prevention of heart failure with cardioprotective therapy after early detection of cardiotoxicity during chemotherapy in cancer patients using CMR Fast-SENC intramyocardial LV & RV strain. ESC Heart Failure 2019.

Title: Classifying heart failure patients based on objective Fast-SENC cardiac MRI measurements instead of subjective NYHA symptomatic criteria

Citation: Steen H, et al. Classifying heart failure patients based on objective Fast-SENC cardiac MRI measurements instead of subjective NYHA symptomatic criteria. ESC Heart Failure 2019.

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain® has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.